glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results LANDMARK ALERT π¨ REPRIEVE Trial results: Pitavastatin provides over 35% reduction in MACE in patients with HIV! Comparative renal outcomes of matched
Description
K., Lin, S., Gupta, N
39 GLP-1RAs and Coronary Artery Disease Epicardial CAD is commonly seen in HFpEF
QT prolongation through hERG K + channel blockade: current knowledge and strategies for the early prediction during drug development
Incidence of injection site reactions is about 4%
Early procedures, like intestinal bypasses and open gastric bypasses in the 1960s, helped patients lose a lot of weight but came with serious risks
Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, et al
